RNK-08954 / Ranok Therap - LARVOL DELTA

A phase 1, first-in-human, open-label study evaluating the safety, tolerability, pharmacokinetics, and efficacy of RNK08954 in patients with advanced solid tumors with a KRAS G12D mutation. (ASCO-GI 2026) - P1/2 | "Clinical Trial Registration Number: NCT06667544 The full, final text of this abstract will be available on Jan 05 at 05:00 PM EST."

Clinical • First-in-human • Metastases • P1 data • PK/PD data • Gastrointestinal Cancer • Oncology • Solid Tumor • KRAS

TRIAD1: A Study of RNK08954 in Subjects With Advanced Solid Tumors With KRAS ((Kirsten Rat Sarcoma) G12D Mutation (clinicaltrials.gov) - P1/2 | N=152 | Recruiting | Sponsor: Ranok Therapeutics (Hangzhou) Co., Ltd. | Initiation date: Jun 2025 ➔ Oct 2024

Trial initiation date • Oncology • Sarcoma • Solid Tumor • KRAS

TRIAD1: A Study of RNK08954 in Subjects With Advanced Solid Tumors With KRAS ((Kirsten Rat Sarcoma) G12D Mutation (clinicaltrials.gov) - P1/2 | N=152 | Recruiting | Sponsor: Ranok Therapeutics (Hangzhou) Co., Ltd. | Not yet recruiting ➔ Recruiting | Initiation date: Dec 2024 ➔ Jun 2025

Enrollment open • Trial initiation date • Oncology • Sarcoma • Solid Tumor • KRAS